newsfilter
← Latest News
GlobeNewswire·

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th.The event